Review: Role of the selective aldosterone receptor blockers in arterial hypertension | Zendy

Cristina Sierra | Zendy; Luís M. Ruilope | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Review: Role of the selective aldosterone receptor blockers in arterial hypertension

Author(s) -

Cristina Sierra,

Luís M. Ruilope

Publication year - 2004

Publication title -

journal of the renin-angiotensin-aldosterone system

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.457

H-Index - 46

eISSN - 1752-8976

pISSN - 1470-3203

DOI - 10.3317/jraas.2004.002

Subject(s) - eplerenone , spironolactone , medicine , aldosterone , cardiology , heart failure , microalbuminuria , myocardial infarction , blockade , left ventricular hypertrophy , mineralocorticoid receptor , candesartan , disease , blood pressure , renin–angiotensin system , receptor

Aldosterone can cause cardiovascular injury in animals and men. The aldosterone blocker, spironolactone, has been shown to reduce mortality in patients with congestive heart failure. The use of this drug in arterial hypertension has been limited by the high frequency of adverse effects. Recently published data with a new aldosterone blocker, eplerenone, have confirmed the benefits of aldosterone blockade in patients post-myocardial infarction, as well as in the regression of left ventricular hypertrophy in hypertensive patients and of microalbuminuria in Type 2 diabetic patients. The fact that eplerenone is much better tolerated open the possibility of this therapy in cardiovascular, as well as in renal disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research